Investor Presentaiton
ASCEND Program-Level Cardiovascular Safety Data
MACE components were generally consistent across treatment groups in all trials*
Patients with events
n/N (%)
Rate per 100 PY
(95% CI)
Daprodustat
Favors
Favors
ESA
Daprodustat
ESA+
Daprodustat
ESAT
All-cause mortality
ASCEND-ND
301/1937
(15.5)
294/1487
298/1935
(15.4)
300/1477
8.35
(7.43, 9.35)
8.27
(7.35, 9.26)
ASCEND-D
(19.8)
(20.3)
8.32
(7.39, 9.32)
8.59
Absolute rate difference
per 100 PY (95% CI)
0.08 (-1.25, 1.41)
-0.28 (-1.63, 1.08)
(7.65, 9.62)
17/157
12/155
ASCEND-ID
(10.8)
18/270
ASCEND-TD
(6.7)
(7.7)
10/137
(7.3)
10.32
(6.01, 16.52)
7.23
(3.74, 12.63)
6.47
(3.84, 10.23)
7.04
(3.37, 12.94)
3.08 (-3.30, 9.47)
-0.56 (-5.85, 4.72)
Myocardial infarction
ASCEND-ND
103/1937
(5.3)
114/1487
97/1935
(5.0)
137/1477
2.94
(2.40, 3.56)
2.76
(2.24, 3.36)
0.18 (-0.61, 0.97)
HH
ASCEND-D
(7.7)
(9.3)
3.34
(2.76, 4.01)
4.08
H◉
-0.74 (-1.66, 0.18)
(3.43, 4.83)
HH
5/157
5/155
ASCEND-ID
(3.2)
11/270
(3.2)
5/137
3.07
(1.00, 7.15)
3.08
-0.01 (-3.82, 3.80)
(1.00, 7.19)
ASCEND-TD
(4.1)
(3.6)
4.03
(2.01, 7.21)
3.58
(1.16, 8.35)
0.45 (-3.48, 4.39)
Stroke
ASCEND-ND
45/1937
(2.3)
43/1487
34/1935
(1.8)
51/1477
1.26
(0.92, 1.69)
0.95
(0.66, 1.33)
0.31 (-0.18, 0.80)
K
ASCEND-D
(2.9)
(3.5)
1.23
(0.89, 1.66)
1.48
(1.10, 1.94)
H◉
-0.25 (-0.79, 0.30)
H+
1/157
1/155
0.61
ASCEND-ID
(0.6)
(0.6)
(0.02, 3.38)
0.60
(0.02, 3.36)
0.00 (-1.67, 1.68)
8/270
0/137
ASCEND-TD
(3.0)
(0.0)
2.92
(1.26, 5.76)
0.00
(0.00, 2.60)
2.92 (0.90, 4.95)
0
5
10
15
20
-10
-5
0
5
10
15
Rate per 100 PY (95% CI)
*Smaller trials (ASCEND-ID, ASCEND-TD and ASCEND-NHQ) reported MACE but were not designed for
formal MACE evaluation; *Darbepoetin alfa (ASCEND-D, -ND, -ID), epoetin alfa (ASCEND-D, -TD).
Absolute rate difference per 100 PY (95% CI)
18View entire presentation